Table of Contents PART I U.S. Studies Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines * MD Anderson Cancer Center Houston, Texas Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines * MD Anderson Cancer Center Houston, Texas The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial. * ISCI / University of Miami Miami, Florida Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs * Medical University of South Carolina Charleston, South Carolina Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells(Rexlemestrocel-L) for the Treatment of Heart Failure. * Mesoblast Investigational Site 10757 - Cardiology, P.C. Birmingham, Alabama * Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital Birmingham, Alabama * Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center Gilbert, Arizona * (and 56 more.) Europe Allogeneic Stem Cell Therapy in Heart Failure * Cardiac Catheterization Laboratory 2014, The Heart Centre, University Hospital, Rigshospitalet Copenhagen Ø, Denmark * Cardiac Catheterization Laboratory 2014, The Heart Centre, University Hospital, Rigshospitalet Copenhagen Ø, Denmark Stem Cells Therapy in Advanced Heart Failure * Celestino Sardu Naples, Italy * Raffaele Marfella Naples, Italy * Celestino Sardu Napoli, Italy Stem Cell Therapy in Ischemic Non-treatable Cardiac Disease * 2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet Copenhagen, Denmark Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.
* Hospital Universitario Puerta del Mar Cádiz, Spain * Hopistal Universitario Reina Sofía Córdoba, Spain * Hospital Universitario Virgen de las Nieves Granada, Spain * (and 6 more.) Cell Therapy in HFpEF * University Medical Center Ljubljana Ljubljana, Slovenia Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure * Zentralklinik Bad Berka Bad Berka, Germany * Goethe University Frankfurt Frankfurt, Germany * Klinikum Fulda Fulda, Germany * (and 3 more.) Impact of Intracoronary Injection of Autologous BMMC for LV Contractility and Remodeling in Patients With STEMI * Polsko-Amerykaoskie Kliniki Serca Ustroo, Poland Stem Cell Therapy in Non-Ischemic Non-treatable Dilated Cardiomyopathies II: a Pilot Study * The Heart Centre, Rigshospitalet University Hospital Copenhagen, Copenhagen, Denmark Iran IMMNC-HF: IntraMyocardial Injection of Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients * Stem Cell and Regenerative Medicine Institute (SCARM) Tabriz, Islamic Republic of Iran ICMNC-HF. IntraCoronary Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients * Stem Cell and Regenerative Medicine Institute (SCARM) Tabriz, Islamic Republic of Iran China Treating Heart Failure With hPSC-CMs * HelpThera Nanjing, Jiangsu, China PART II Type 1 Diabetes US Studies China China/Spain South America Canada Middle East Sweden Type 2 Diabetes US Studies China Near East Vietnam Other Thoughts.